October 15, 2025
Grant award provides MD/PhD candidates with funding and expertise to translate promising scientific discoveries into medicines October 15, 2025, CLEVELAND, OH – Harrington Discovery Institute at University Hospitals and Case Western Reserve University School of Medicine have issued a call for proposals for the 2026...
Continue ReadingDecember 21, 2023
The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading
December 13, 2023
The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading
December 08, 2023
Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading
December 05, 2023
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading
November 30, 2023
Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading
October 25, 2023
ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading
October 18, 2023
First Ten Years. Accelerating Discoveries into Medicines. Continue Reading
October 04, 2023
Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading
October 03, 2023
The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years. Continue Reading
September 29, 2023
Aleta hopes to initiate the registrational trial investigating ALETA-001 in B-cell malignancies in 2024/25. Continue Reading